SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors bet on a potential short squeeze fueled by record-high short interest and anticipation surrounding the company's upcoming acquisition of Northern Data. The community is actively discussing the stock's long-term growth potential through cloud infrastructure expansion and the strategic backing of Tether, which remains a key catalyst for bullish sentiment.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings Limited (WSHP) is currently experiencing intense volatility and social media attention as traders monitor aggressive price swings often associated with low-float momentum plays. The community is actively debating the stock's potential for dramatic short squeezes while warning of the risks inherent in such speculative, high-volume trading activity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is surging on heavy volume as investors react to regulatory news regarding the potential easing of restrictions on peptide access, fueling speculation of a major short squeeze given the stock's significant short interest. The community is actively debating the sustainability of this rally, with many traders drawing parallels to past momentum runs and expressing strong conviction in the company's platform-driven growth strategy.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community focus as traders debate the potential for a short squeeze amid high short interest and a perceived "bear trap" setup following a dip in share price. Investors are actively discussing the company's "Opendoor 2.0" turnaround strategy, specifically highlighting rising weekly home acquisition numbers and institutional confidence as catalysts that could drive a re-rating once the housing market stabilizes.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to strong bullish momentum fueled by hyperscalers like Meta doubling down on AI infrastructure investments, leading the community to discuss its potential to challenge competitors. Investors are actively debating the stock's path toward new all-time highs, with many closely watching key technical resistance levels while navigating significant speculative chatter regarding potential price targets.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing significant volatility driven by the appointment of a new CEO and a fresh $1 billion capital infusion from the PIF and Uber, though investors remain sharply divided over ongoing dilution concerns and operational hurdles. While some community members view the strategic partnership and robotaxi expansion as a long-term catalyst, others are actively shorting the stock due to consistent production misses, vehicle recalls, and the company's persistent cash burn.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently in the spotlight following an analyst upgrade to outperform and a significant capital raise that bolsters its balance sheet for future growth. The community is buzzing with excitement over the upcoming Neutron rocket launch, while ongoing discussions focus on the company's strategic acquisitions and its strengthening position within the aerospace and defense sectors as a prime contractor.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies has become a focal point for traders due to its recent public listing and status as a pure-play photonic quantum computing company. The community is actively debating the stock's significant volatility, low-float dynamics, and potential for a short squeeze, while weighing the company's ambitious technological goals against its early-stage financial profile.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a combination of high-volume momentum, a new contract with DARPA for the HARQ program, and positive sector sentiment sparked by Nvidia's launch of open-source quantum AI models. While community discourse remains polarizedwith bulls cheering the breakout and the potential for a short squeeze, and bears warning of fundamental weaknesses and valuation concernstraders are actively debating whether this is a sustainable sector rotation or a recurring short-term hype cycle.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing intense volatility fueled by a high-profile short squeeze, leading to frequent trading halts and dramatic price swings. Community discourse is deeply divided, with some investors betting on a continued parabolic rise toward record highs, while others argue the stock is a 'meme' play disconnected from fundamentals and facing impending share dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50 Day Moving Average - Here's Why...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) was the recipient of a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling...

Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $22.00 price target on shares of Seres Therapeutics in a research report on Friday...

Seres Therapeutics (NASDAQ:MCRB) Issues Earnings Results

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.76) earnings per share for the quarter, beating analysts...

Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday

Seres Therapeutics (NASDAQ:MCRB) will be releasing its Status update earnings before the market opens on Thursday, March 12. (View Earnings Report at...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - What's Next?

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Should You Sell...

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.<h2 class="st-heading-2">Why Did Seres Pause The Study?</h2>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.<h2 class="st-heading-2">Extending Cash Runway</h2>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.<stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra">Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Equity

Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average - Time to Sell?

Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below Fifty Day Moving Average - Here's What Happened...

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened

Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average - Here's What Happened...

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Current Price	$8.84
Prev Close	$8.84
Open	$8.93
Dividend Yield	0.00%
50-Day Moving Average	$9.56
Beta	1.06
Avg. Volume	47,783.96
PE Ratio	10.91

52-Week High	$29.98
52-Week Low	$6.53
Market Capitalization	$84.74M
EPS (Annual)	$0.6422
Price to Book	1.91
Revenue Per Employee	$11,954.55

MCRB
Seres Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MCRB News

MCRBSeres Therapeutics Inc